GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
1. GSK reported Q4 sales of $10.40 billion, beating analyst expectations. 2. Vaccine sales fell 14%, with Arexvy significantly impacted by low demand. 3. Specialty Medicines grew 14%, primarily driven by HIV and asthma drug sales. 4. GSK plans £2 billion share buyback over 18 months, boosting EPS outlook. 5. Long-term sales outlook raised to over £40 billion by 2031.